Literature DB >> 32568823

An Integrative Morphomolecular Classification System of Gastric Carcinoma With Distinct Clinical Outcomes.

Jia-Huei Tsai1,2, Yung-Ming Jeng1,2, Kuo-Hsing Chen3,4,5, Chia-Hsiang Lee1, Chang-Tsu Yuan1, Jau-Yu Liau1,2.   

Abstract

A robust morphomolecular classification system for gastric carcinoma is required. A 4-tier morphologic classification is proposed, including diffuse, intestinal, tubular, and lymphoid types. A tissue microarray for mismatch repair immunohistochemistry and Epstein-Barr virus (EBV) in situ hybridization were performed in 329 gastric carcinomas. DNA flow cytometry was used to detect aneuploidy in formalin-fixed paraffin-embedded samples. Lymphoid histology was the third most common histologic pattern at our institute and strongly associated with EBV infection and PMS2/MLH1-deficiency (both P<0.001). HER2 overexpression and SATB2 expression more frequently occurred in intestinal histology (both P<0.001). Loss of ARID1A expression was strikingly associated with lymphoid histology (P<0.001) and negative E-cadherin expression was correlated with diffuse histology (P=0.001). Programmed death-ligand 1 expression was most frequently present in lymphoid-type gastric carcinoma than other histologic subtypes and correlated with the molecular features of PMS2/MLH1-deficiency and EBV infection (all P<0.001). Aneuploidy was detected in 53% of gastric carcinomas and was highly correlated with intestinal type and the least with the lymphoid type (P<0.001). Notably, lymphoid-type gastric carcinoma showed the best outcome, whereas tubular type showed the worst survival rate (P<0.001). We integrated aneuploidy with morphologic patterns to propose a morphomolecular classification scheme, which served as a successful and independent prognostic factor in multivariate 5-year disease-free survival analysis (P<0.001). Overall, we describe an integrated morphomolecular classification system for gastric carcinomas to effectively predict patient outcomes. This system is cost-effective and reliable and can help select target therapeutics and facilitate clinical management.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32568823     DOI: 10.1097/PAS.0000000000001521

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  3 in total

1.  Analysis of clinicopathological and molecular features of crawling-type gastric adenocarcinoma.

Authors:  Yasuko Fujita; Noriyuki Uesugi; Ryo Sugimoto; Makoto Eizuka; Yosuke Toya; Risaburo Akasaka; Takayuki Matsumoto; Tamotsu Sugai
Journal:  Diagn Pathol       Date:  2020-09-17       Impact factor: 2.644

Review 2.  The seen and the unseen: Molecular classification and image based-analysis of gastrointestinal cancers.

Authors:  Corina-Elena Minciuna; Mihai Tanase; Teodora Ecaterina Manuc; Stefan Tudor; Vlad Herlea; Mihnea P Dragomir; George A Calin; Catalin Vasilescu
Journal:  Comput Struct Biotechnol J       Date:  2022-09-12       Impact factor: 6.155

Review 3.  Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges.

Authors:  José Garcia-Pelaez; Rita Barbosa-Matos; Irene Gullo; Fátima Carneiro; Carla Oliveira
Journal:  Mol Oncol       Date:  2021-05-02       Impact factor: 6.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.